Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.89
-0.30 (-2.11%)
Official Closing Price
Updated: 4:10 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
The Hot List: 3 AI Stocks Worth Buying on Weakness
March 01, 2024
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
February 12, 2024
Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies.
Via
Benzinga
Exposures
Product Safety
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study
February 09, 2024
Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.
Via
Benzinga
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
February 01, 2024
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
Via
Benzinga
3 Stocks to Buy to Benefit From the Booming Sleep Industry
January 23, 2024
It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation.
Via
InvestorPlace
Looking Into Takeda Pharmaceutical's Recent Short Interest
January 15, 2024
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
December 25, 2023
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
December 07, 2023
Via
Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
November 21, 2023
Via
Benzinga
Earnings Scheduled For February 1, 2024
February 01, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
November 03, 2023
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...
Via
Benzinga
One Ultra-Cheap High-Yield Dividend Stock to Buy
December 22, 2023
Now may be a good time for dividend investors to consider loading up on this stock.
Via
The Motley Fool
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
December 19, 2023
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...
Via
Benzinga
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
October 19, 2023
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
October 11, 2023
Via
Benzinga
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
October 04, 2023
Via
Benzinga
Why Is Neurocrine Biosciences Stock Trading Lower Today?
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
November 10, 2023
The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE:
Via
Benzinga
Exposures
Product Safety
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
October 23, 2023
Analysts say Alkermes' drug is clearly active. But investors have concerns.
Via
Investor's Business Daily
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
October 21, 2023
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...
Via
Talk Markets
Earnings Scheduled For October 26, 2023
October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
Via
Benzinga
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
October 18, 2023
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF).
Via
Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial
October 03, 2023
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 02, 2023
Via
Benzinga
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So.
October 02, 2023
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that...
Via
Benzinga
Topics
Economy
Exposures
Economy
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.